에스토니아 - 에스토니아어 - Ravimiamet

pfizer europe ma eeig - metüülprednisoloon - tablett - 4mg 100tk; 4mg 30tk

에스토니아 - 에스토니아어 - Ravimiamet

pfizer europe ma eeig - metüülprednisoloon - süstesuspensioon - 40mg 1ml 2ml 1tk; 40mg 1ml 1ml 1tk

에스토니아 - 에스토니아어 - Ravimiamet

pfizer europe ma eeig - metüülprednisoloon - süstelahuse pulber ja lahusti - 500mg 1tk

에스토니아 - 에스토니아어 - Ravimiamet

teva pharma b.v. - metüülprednisoloon - süstelahuse pulber - 500mg 3tk; 500mg 10tk

에스토니아 - 에스토니아어 - Ravimiamet

pfizer europe ma eeig - metüülprednisoloon - tablett - 16mg 50tk

에스토니아 - 에스토니아어 - Ravimiamet

pfizer europe ma eeig - metüülprednisoloon - süstelahuse pulber ja lahusti - 40mg 1tk

에스토니아 - 에스토니아어 - Ravimiamet

pfizer europe ma eeig - metüülprednisoloon - süstelahuse pulber ja lahusti - 250mg 1tk

에스토니아 - 에스토니아어 - Ravimiamet

pfizer europe ma eeig - metüülprednisoloon - süstelahuse pulber ja lahusti - 125mg 1tk

에스토니아 - 에스토니아어 - Ravimiamet

pfizer europe ma eeig - metüülprednisoloon - süstelahuse pulber ja lahusti - 1000mg 1tk

유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - abirateroonatsetaat - eesnäärmevähk - endokriinset ravi - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.